New drug shows promise in slowing lung cancer that spread to the brain

NCT ID NCT03653546

Completed Disease control Sponsor: Alpha Biopharma (Jiangsu) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 05, 2026 · Updated 36 times

Summary

This study tested a new pill called AZD3759 against standard targeted therapies (gefitinib or erlotinib) as a first treatment for people with advanced non-small cell lung cancer that has a specific gene mutation (EGFR) and has spread to the brain. The trial involved 492 adults. The goal was to see if AZD3759 could delay cancer growth better than the usual drugs. Results showed that AZD3759 improved the time before the cancer worsened, especially in the brain.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

China site

Hefei, Anhui, 230001, China
China site

Chongqing, China, 400037, China
China site

Fuzhou, Fujian, 350014, China
China site

Xiamen, Fujian, 361003, China
China site

Guangzhou, Guangdong, 510080, China
China site

Guangzhou, Guangdong, 510180, China
China site

Haerbin, Heilongjiang, 150081, China
China site

Zhengzhou, Henan, 450008, China
China site

Zhengzhou, Henan, 450052, China
China site

Wuhan, Hubei, 430022, China
China site

Wuhan, Hubei, 430030, China
China site

Wuhan, Hubei, 430079, China
China site

Yichang, Hubei, 443003, China
China site

Changsha, Hunan, 410013, China
China site

Nanjing, Jiangsu, 210002, China
China site

Nanjing, Jiangsu, 210009, China
China site

Suzhou, Jiangsu, 215004, China
China site

Wuxi, Jiangsu, 214062, China
China site

Xuzhou, Jiangsu, 221002, China
China site

Yangzhou, Jiangsu, 225001, China
China site

Changchun, Jilin, 130012, China
China site

Changchun, Jilin, 130021, China
China site

Xi'an, Shaanxi, 710061, China
China site

Linyi, Shandong, 276000, China
China site

Weifang, Shandong, 261000, China
China site

Yantai, Shandong, 264000, China
China site

Chengdu, Sichuan, 610041, China
China site

Kunming, Yunnan, 650118, China
China site

Hangzhou, Zhejiang, 310003, China
China site

Hangzhou, Zhejiang, 310022, China
China site

Hangzhou, Zhejiang, 311100, China
China site

Beijing, 100021, China
China site

Beijing, 100071, China
China site

Beijing, 100142, China
China site

Beijing, 100730, China
China site

Chongqing, 400030, China
China site

Chongqing, 400042, China
China site

Shanghai, 200030, China
China site

Shanghai, 200032, China
China site

Tianjin, 300052, China
China site 0123

Jinan, Shandong, 250117, China
Korea Site

Seoul, 03080, South Korea
Korea Site

Seoul, 06351, South Korea
Korea Site

Taebuk, 28644, South Korea
Korea site

Daegu, 42415, South Korea
Korea site

Gyeonggi-do, 16247, South Korea
Korea site

Gyeongsang, 52727, South Korea
Korea site

Incheon, 21565, South Korea
Korea site

Seoul, 05368, South Korea
Korea site

Seoul, 06591, South Korea
Korea site

Seoul, 07061, South Korea
Korea site

Suwon, 16499, South Korea
Korea site

Ulsan, 44033, South Korea
Singapore site

Singapore, 308433, Singapore
Taiwan site

Taichung, 407, Taiwan
Taiwan site

Tainan, 704, Taiwan
Taiwan site

Taipei, 100, Taiwan
Taiwan site

Taoyuan, 333, Taiwan

Conditions

Explore the condition pages connected to this study.

BRAIN METASTASES EGFR GENE MUTATION NON SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER